US Stock Insider Trading | Ernexa disclosed one insider transaction on February 17

K-LinePoet · 2026-02-21T15:09:20+00:00

On February 17, 2026, Ernexa (ERNA) disclosed an insider transaction. Shareholder Cherington Charles, who owns more than 10%, bought 4 million shares on February 10, 2026.【Recent Insider Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 17, 2026 | Shareholder owning over 10% | Cherington Charles | February 10, 2026 | Buy | 4,000,000 | 0.50 |

K-LinePoet

2026-02-21 15:09:20

On February 17, 2026, Ernexa (ERNA) disclosed a company insider trading activity. Shareholder Cherington Charles, holding more than 10% of shares, purchased 4 million shares on February 10, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Shareholder with over 10%	Cherington Charles	February 10, 2026	Buy	4,000,000	0.50	2,000,000
June 11, 2025	Shareholder with over 10%	Cherington Charles	June 9, 2025	Buy	21,241,200	0.10	2,221,800
April 4, 2025	Shareholder with over 10%	Cherington Charles	April 2, 2025	Buy	3,768,400	0.10	394,200
November 5, 2024	Shareholder with over 10%	Cherington Charles	October 29, 2024	Buy	2,819,500	0.50	1,409,800
June 25, 2024	Executive	Gurrola Sandra M	June 21, 2024	Sell	180	1.94	349.20
June 23, 2023	Executive	Gurrola Sandra M	June 21, 2023	Sell	179	2.48	443.92
December 6, 2022	Shareholder with over 10%	Cherington Charles	December 2, 2022	Buy	261,800	3.28	858,600
December 6, 2022	Director	Singer Nicholas Jason	December 2, 2022	Buy	283,300	3.28	929,200
December 5, 2022	Shareholder with over 10%	HALPERN JOHN D	December 2, 2022	Buy	335,900	3.28	1,101,800
June 29, 2022	Executive	DAmour Kevin	June 28, 2022	Sell	6,077	0.55	3,363.01

[Company Profile]

Ernexa Therapeutics Inc. was incorporated in Delaware in 1984. Ernexa is a late-stage biopharmaceutical company focused on therapies based on IL-2 cytokines for cancer patients. Ernexa is dedicated to developing IRX-2, a novel cytokine-based therapy for cancer treatment. The active components of IRX-2, including IL-2 and other key cytokines, are believed to signal, enhance, and restore immune functions suppressed by tumors, enabling the immune system to attack cancer cells.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.